Counteracting inflammation: A promising therapy in cachexia

Critical Reviews in Oncogenesis

Volumn 17, Issue 3, 2012, Pages 253-262

  Argilés, Josep M ^a   López Soriano, Francisco J ^a   Busquets, Sílvia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cachexia; Inflammation; Muscle wasting

Indexed keywords

BRANCHED CHAIN AMINO ACID; C REACTIVE PROTEIN; CLAZAKIZUMAB; DOCETAXEL; ETANERCEPT; GAMMA INTERFERON; GLUTAMINE; ICOSAPENTAENOIC ACID; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; OMEGA 3 FATTY ACID; SULFATE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ARTICLE; BODY MASS; BONE MARROW; CACHEXIA; CHRONIC WASTING DISEASE; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIVER CELL; MUSCLE ATROPHY; MUSCLE CELL; NERVE CELL; NUTRIENT; PARENTERAL NUTRITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; CACHEXIA; CYTOKINES; HUMANS; WASTING SYNDROME;

EID: 84863836287     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v17.i3.30     Document Type: Article

References (61)

1. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi-Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr. 2008;27:7939.
2. Argiles JM, Busquets S, Lopez-Soriano FJ. Thepivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol. 2005;37:160919.
3. Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care. 2009;3:26368.
4. Mantovani G, Maccio A, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Madeddu C, Dessi A. Serum levels of leptin and proinflammatory cyto kines in patients with advancedstage cancer at different sites. J Mol Med. 2000;78:55461.
5. Reid MB, Li YP. Tumor necrosis factoralpha and muscle wasting: a cellular perspective. Respir Res. 2001;2:26972.
6. Constantinou C, Fontes de Oliveira CC, Mintzopoulos D, Busquets S, He J, Kesarwani M, Mindrinos M, Rahme LG, Argiles JM, Tzika AA. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model ofcancer cachexia. Int J Mol Med. 2011;27:1524.
7. Han Y, Weinman S, Boldogh I, Walker RK, Brasier AR. Tumor necrosis factoralphainducible IkappaBalpha proteolysis mediated by cytosolic mcalpain. A mechanism parallel to the ubiquitin proteasome pathway for nuclear factorkappab activation. J Biol Chem. 1999;274:78794.
8. Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Murai M. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urol ogy. 2007;69:1137.
9. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992;89:16814.
10. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL6, inhibits human tumorinduced cachexia in nude mice. Int J Cancer. 2004;111:59295.
11. Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexiainducing and noninducing clones of murine colon 26 carcinoma. Int J Cancer. 1995;61:5228.
12. Matthys P, Heremans H, Opdenakker G, Billiau A. Antiinterferongamma antibody treatment, growth of Lewis lung tumors in mice and tumorassociated cachexia. Eur J Cancer. 1991;27:1827.
13. Costelli P, Llovera M, Carbo N, Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Interleukin1 receptor antagonist (IL1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH130). Cancer Lett. 1995;95:338.
14. Henderson JT, Mullen BJ, Roder JC. Physiologi cal effects of CNTFinduced wasting. Cytokine. 1996;8:78493.
15. Wang MC, Forsberg NE. Effects of ciliary neu rotrophic factor (CNTF) on protein turnover in cultured muscle cells. Cytokine. 2000;12:418.
16. Evans RD, Argiles JM, Williamson DH. Metabolic effects of tumor necrosis factoralpha (cachectin) and interleukin1. Clin Sci (Lond). 1989;77:35764.
17. Yamamoto N, Kawamura I, Nishigaki F, Tsujimoto S, Naoe Y, Inami M, Elizabeth L, Manda T, Shimomura K. Effect of FR143430, a novel cytokine sup pressive agent, on adenocarcinoma colon26induced cachexia in mice. Anticancer Res. 1998;18:13944.
18. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human mono cytes. J Exp Med. 1991;173:699703.
19. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168:40814.
20. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54:5405.
21. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002;86:12330.
22. Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose intensive chemotherapy in cancer patients. J Clin Oncol. 2006;24:18529.
23. Steffen BT, Lees SJ, Booth FW. AntiTNF treatment reduces rat skeletal muscle wasting in monocrotalineinduced cardiac cachexia. J Appl Physiol. 2008;105:19508.
24. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, Caprioni F, Van Cutsem E, Richel D, DeWitte M, Qi M, Robinson D, Jr., Zhong B, De Boer C, Lu JD, Prabhakar U, Corringham R, Von Hoff D. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol. 2008;6:1825.
25. Clarke SJ, Gebbie, C, Sweeney, C, Olszewski, N, Smith, J. A phase I, pharmacokinetic (PK) and preliminary efficacy assesssment of ALD518, a humanized antiinterleukin (IL)6 antibody, in patients with advanced cancer. J Cachexia Sarc Muscle. 2010;1:98101.
26. Quinn LS, Haugk KL, Grabstein KH. Interleu kin15: a novel anabolic cytokine for skeletal muscle. Endocrinology. 1995;136:366972.
27. Carbo N, Lopez-Soriano J, Costelli P, Alvarez B, Busquets S, Baccino FM, Quinn LS, Lopez-Soriano FJ, Argiles JM. Interleukin15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim Biophys Acta. 2001;1526:1724.
28. Figueras M, Busquets S, Carbo N, Barreiro E,.Almendro V, Argiles J.M,.Lopez-Soriano F.J. Inter leukin15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumorbearing rats. FEBS Lett. 2004;569:2016.
29. Busquets S, Figueras MT, Meijsing S, Carbo N, Quinn LS, Almendro V, Argiles JM, Lopez-Soriano FJ. Interleukin15 decreases proteolysis in skeletal muscle: a direct effect. Int J Mol Med. 2005;16:4716.
30. Argiles JM, Lopez-Soriano FJ, Busquets S. Therapeutic potential of interleukin15: a myokine involved in muscle wasting and adiposity. Drug Discov Today. 2009;14:20813.
31. Argiles JM, Lopez-Soriano FJ, Busquets S. Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr Opin Support Palliat Care. 2007;1:2938.
32. Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008;101:8E10E.
33. Pasini E, Aquilani R, Dioguardi FS, D'Antona G, Gheorghiade M, Taegtmeyer H. Hypercatabolic syndrome: molecular basis and effects of nutritional supplements with amino acids. Am J Cardiol. 2008;101:11E15E.
34. Tayek JA, Bistrian BR, Hehir DJ, Martin R, Moldawer LL, Blackburn GL. Improved protein kinetics and albumin synthesis by branched chain amino acidenriched total parenteral nutrition in cancer cachexia. A prospective randomized crossover trial. Cancer. 1986;58:147157.
35. Hunter DC, Weintraub M, Blackburn GL, Bistrian BR. Branched chain amino acids as the protein component of parenteral nutrition in cancer cachexia. Br J Surg. 1989;76:14953.
36. Cangiano C, Laviano A, Meguid MM, Mulieri M, Conversano L, Preziosa I, Rossi-Fanelli F. Effects of administration of oral branchedchain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst. 1996;88:5502.
37. Krause R, James JH, Ziparo V, Fischer JE. Brain tryptophan and the neoplastic anorexiacachexia syndrome. Cancer. 1979;44:10038.
38. Meguid MM, Muscaritoli M, Beverly JL, Yang ZJ, Cangiano C, Rossi-Fanelli F. The early cancer anorexia paradigm: changes in plasma free trypto phan and feeding indexes. JPEN J Parenter Enteral Nutr. 1992;16:56S59S.
39. Fernstrom JD. Dietary effects on brain serotonin synthesis: relationship to appetite regulation. Am J Clin Nutr. 1985;42:107282.
40. Faber J, Vos P, Kegler D, van Norren K, Argiles JM, Laviano A, Garssen J, van Helvoort A. Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia. Br J Cancer. 2008;99:202936.
41. van Norren K, Kegler D, Argiles JM, Luiking Y, Gorselink M, Laviano A, Arts K, Faber J, Jansen H, van der Beek EM, van Helvoort A. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumorbearing cachec tic mice. Br J Cancer. 2009;100:71322.
42. Nunes EA, Kuczera D, Brito GA, Bonatto SJ, Yamazaki RK, Tanhoffer RA, Mund RC, Kryczyk M, Fernandes LC. Betahydroxybetamethylbutyrate supplementation reduces tumor growth and tumor cell proliferation ex vivo and prevents cachexia in Walker 256 tumorbearing rats by modifying nuclear factorkappaB expression. Nutr Res. 2008;28:48793.
43. Souba WW. Glutamine and cancer. Ann Surg. 1993;218:71528.
44. Rivera S, Azcon-Bieto J, LopezSoriano FJ, Miral peix M, Argiles JM. Amino acid metabolism in tumorbearing mice. Biochem J. 1988;249:4439.
45. Chen MK, Salloum RM, Austgen TR, Bland JB, Bland KI, Copeland EM, 3rd, Souba WW. Tumor regulation of hepatic glutamine metabolism. JPEN J Parenter Enteral Nutr. 1991;15:15964.
46. Ziegler TR, Young LS, Benfell K, Scheltinga M, Hortos K, Bye R, Morrow FD, Jacobs DO, Smith RJ, Antin JH, Wilmore DW. Clinical and metabolic efficacy of glutaminesupplemented parenteral nutrition after bone marrow transplantation. A randomized, doubleblind, controlled study. Ann Intern Med. 1992;116:8218.
47. Klimberg VS, Nwokedi E, Hutchins LF, Pappas AA, Lang NP, Broadwater JR, Read RC, Westbrook KC. Glutamine facilitates chemotherapy while reducing toxicity. JPEN J Parenter Enteral Nutr. 1992;16:83S87S.
48. Laviano A, Renvyle T, Yang ZJ. From laboratory to bedside: new strategies in the treatment of malnutri tion in cancer patients. Nutrition. 1996;12:11222.
49. Droge W, Gross A, Hack V, Kinscherf R, Schykowski M, Bockstette M, Mihm S, Galter D. Role of cysteine and glutathione in HIV infection and cancer cachexia: therapeutic intervention with Nacetylcysteine. Adv Pharmacol. 1997;38:581600.
50. Anti M, Marra G, Armelao F, Bartoli GM, Ficarelli R, Percesepe A, De Vitis I, Maria G, Sofo L, Rapaccini GL. Effect of omega3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology. 1992;103:88391.
51. Rose DP, Connolly JM. Effects of dietary omega3 fatty acids on human breast cancer growth and metastases in nude mice. J Natl Cancer Inst. 1993;85:17437.
52. Tisdale MJ. Mechanism of lipid mobilization asso ciated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotideregulatory protein. Prostaglandins Leukot Essent Fatty Acids. 1993;48:1059.
53. Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, Giacosa A, Van Gossum A, Bauer J, Barber MD, Aaronson NK, Voss AC, Tisdale MJ. Effect of a protein and energy dense N3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a ran domised double blind trial. Gut. 2003;52:147986.
54. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD. Doubleblind, placebocontrolled, randomized study of eicosapen taenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24:34017.
55. Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev. 2007:CD004597.
56. Read JA, Beale PJ, Volker DH, Smith N, Childs A, Clarke SJ. Nutrition intervention using an eicosa pentaenoic acid (EPA)containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer. 2007;15:3017.
57. van der Meij BS, Langius JA, Smit EF, Spreeuwenberg MD, von Blomberg BM, Heijboer AC, Paul MA, van Leeuwen PA. Oral nutritional supplements containing (n3) polyunsaturated fatty acids affect the nutritional status of patients with stage III nonsmall cell lung cancer during multimodality treatment. J Nutr. 2010;140:177480.
58. Bayram I, Erbey F, Celik N, Nelson JL, Tanyeli A. The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancyrelated weight loss in children. Pediatr Blood Cancer. 2009;52:5714.
59. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce antiinflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant. 2006;25:8348.
60. Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, Dessi M, Panzone F, Contu P. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15:20011.
61. Mantovani G, Maccio A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anticyclooxygenase2 showing efficacy and safety in patients with cancerrelated anorexia/cachexia and oxidative stress. Cancer Epi demiol Biomarkers Prev. 2006;15:10304.